These trials showed clinically considerable pharmacokinetic interactions [7] characterized by a minimize during the clearance in the anticancer drug and for this reason increased exposure. The interpretation of subsequent phase II and III medical trials was challenging because it was impossible to administer a similar dose of chemotherapy within th… Read More